肌炎影像学:概述与更新
本文综述特发性炎症性肌病的影像学评估。MRI 是肌肉评估的主要方法,可显示水肿、筋膜及皮下炎症、脂肪替代和萎缩;全身 MRI 可描绘疾病分布,Dixon 脂肪分数和 T2 mapping 提供客观活动性与慢性损伤指标。18F-FDG PET/CT 提供全身代谢信息,可识别肌肉炎症、间质性肺病、其他系统表现及隐匿恶性肿瘤,但生理性肌肉摄取和采集量化方案异质性限制特异性。
要点
- MRI 是肌炎肌肉评估的主要方法,无电离辐射。
- 全身 MRI 可描绘疾病分布,定量技术提供客观指标。
- FDG PET/CT 可辅助识别肌肉炎症、间质性肺病及隐匿恶性肿瘤。
核心结论
- MRI 仍是肌炎肌肉评估的主要方法,FDG PET/CT 提供互补的全身代谢信息。
研究设计与样本
- 本文为综述,总结主要肌炎表型的影像学模式,对比 MRI、超声、FDG PET/CT、PET/MRI 及新兴示踪剂的既定用途与研究用途。
主要发现
- MRI 可显示水肿、筋膜和皮下炎症、脂肪替代和萎缩,无电离辐射。
- 全身 MRI 描绘疾病分布,Dixon 脂肪分数和 T2 mapping 提供活动性和慢性损伤的客观指标。
- 18F-FDG PET/CT 可识别肌肉炎症、间质性肺病、其他系统表现和隐匿恶性肿瘤。
- 生理性肌肉摄取及采集和量化方案异质性限制 PET 特异性,无法通用 PET 阈值。
- FAPI PET 是新兴的靶向通路方法,在肌肉和肌炎相关肺病中有初步证据。
关键数值与推荐
- MRI 为肌肉评估的主要方法,无电离辐射。
- 超声便携、廉价,但操作者依赖和标准化有限限制全面评估。
- PET/MRI 结合代谢和结构特征,但支持常规使用的证据有限。
临床怎么用
- 影像学支持肌炎表型分型、活检定位、疾病负担评估和监测。
- FDG PET/CT 可在选定患者中识别肌肉炎症、间质性肺病、其他系统表现及隐匿恶性肿瘤。
局限性
- 生理性肌肉摄取和异质性采集量化方案限制 FDG PET/CT 特异性。
- 超声操作者依赖和标准化有限限制全面评估。
- PET/MRI 常规使用的证据有限。
- FAPI PET 仅有初步证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic inflammatory myopathies (IIMs) are heterogeneous autoimmune disorders that affect skeletal muscle and may involve the skin, lungs, heart, gastrointestinal tract, or be associated with malignancy. Imaging supports phenotyping, biopsy targeting, assessment of disease burden, and monitoring. Magnetic resonance imaging (MRI) remains the principal modality for muscle assessment, depicting edema, fascial and subcutaneous inflammation, fatty replacement, and atrophy without ionizing radiation. Whole-body MRI maps disease distribution, whereas quantitative techniques, including Dixon fat-fraction imaging and T2 mapping, provide objective measures of activity and chronic damage. Ultrasound offers a portable, inexpensive adjunct, although operator dependence and limited standardization restrict comprehensive assessment. For nuclear medicine, 18F-fluorodeoxyglucose (FDG) PET/CT provides a complementary whole-body measure of metabolism, potentially identifying muscle inflammation, interstitial lung disease, other systemic manifestations, and occult malignancy in selected patients. Physiologic muscle uptake and heterogeneous acquisition and quantification protocols limit specificity and prevent universal PET thresholds. Hybrid PET/MRI combines metabolic and structural characterization, but evidence supporting routine use remains limited. Fibroblast activation protein inhibitor (FAPI) PET is an emerging pathway-targeted approach with preliminary evidence in muscle and myositis-associated lung disease. This review summarizes imaging patterns across major myositis phenotypes, contrasts established and investigational uses of MRI, ultrasound, FDG PET/CT, PET/MRI, and emerging tracers, illustrates important mimics and pitfalls, and proposes a practical multimodality imaging approach.
引用
- Dabiri M, Ahlawat S, Shaghaghi R, et al. Imaging of myositis: An overview and update. Semin Nucl Med. 2026. PMID: 42951718. doi:10.1053/j.semnuclmed.2026.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。